Concepedia

The risks of therapeutic misconception and individual patient (n= 1) “trials” in rare diseases such as Duchenne dystrophy

Pat Furlong, Elizabeth Vroom, Gert‐Jan B. van Ommen, E. Niks, C.S.M. Straathof, Jan J.G.M. Verschuuren, Annemieke Aartsma‐Rus, Annemieke Aartsma‐Rus, Alessandra Ferlini, Lynn Hagger,

Neuromuscular Disorders · 2010 · 22 citations · 3 references

DOI

Concepts

References

3

Placebos and placebo effects in medicine: historical overview

Anton J.M. de Craen, Ted J. Kaptchuk, Jan G.P. Tijssen et al. · Journal of the Royal Society of Medicine · 1999 · 214 citations · Full text

, , +11

The development of antisense oligonucleotide therapies for Duchenne muscular dystrophy: Report on a TREAT-NMD workshop hosted by the European Medicines Agency (EMA), on September 25th 2009

Francesco Muntoni · Neuromuscular Disorders · 2010 · 56 citations · Full text

, , +14

N-of-1 Trials of Expensive Biological Therapies<subtitle>A Third Way?</subtitle>

Richard L. Kravitz · Archives of Internal Medicine · 2008 · 19 citations · Full text

, , +13